RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
|
|
- Belinda Perry
- 5 years ago
- Views:
Transcription
1 RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA
2 Background Bictegravir (BIC; B) is a novel, unboosted integrase strand transfer inhibitor (INSTI) Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single tablet regimen (STR) recently approved by the US FDA for treatment of HIV-1 infection in treatment-naïve and virologically suppressed adults without resistance to its components Two Phase 3 studies of treatment-naïve participants (1489 and 1490) Two Phase 3 studies of virologically suppressed participants (1844 and 1878) No development of resistance to B/F/TAF
3 Outline BIC In Vitro Resistance Profile Efficacy Outcomes at Week 48 Pre-Existing Resistance Substitutions and B/F/TAF Treatment Outcomes Future Clinical Trials of B/F/TAF
4 HIV-1 PhenoSense IN Assay with Integrase Site-Directed Mutations Bictegravir has a Favorable Cross-Resistance Profile Single Primary Mutations Fold Change vs WT IN Genotype BIC DTG EVG RAL T66I T66A T66K E92Q E92G T97A F121Y Single Primary Mutations Fold Change vs WT IN Genotype BIC DTG EVG RAL Y143R Y143H Y143C S147G Q148R Q148H Q148K N155H R263K EC 50 Fold Change (FC) vs Reference Wild Type < 2.5 BIC 2.5 to < 10 BIC 10 BIC < 4.0 DTG 4.0 to < 13 DTG 13 DTG < 2.5 EVG 2.5 EVG < 1.5 RAL 1.5 RAL Margot et al.; Submitted
5 HIV-1 PhenoSense IN Assay with Clinical Isolates Bictegravir has a Favorable Cross-Resistance Profile G140A/C/S + Q148H/R/K +/- other IN Genotype Fold Change vs WT DTG BIC G140S,Q148H G140S,Q148H G140S,Q148H G140S,Q148H G140S,Q148H E138K,G140S,Q148H G140S,Q148H G140A/C/S + Q148H/R/K +/- other IN Genotype Fold Change vs WT DTG BIC E138K,G140S,Q148H G140S,Q148H G140S,Q148R E138K,G140C,Q148R L74L/M,G140A,Q148R L74M,G140C,Q148R L74L/M,G140A,Q148R L74M,G140C,Q148R E138A, G140S,Q148H G140S,Q148H G140A/C/S + Q148H/R/K +/- other IN Genotype Fold Change vs WT DTG BIC E138K,G140S,Q148H G140S,Q148H T97A,G140S,Q148H T97A,G140S,Q148H G140S,Q148R E138K,G140A,Q148K BIC has an improved resistance profile compared to DTG (p=0.037) EC 50 Fold Change (FC) vs Reference Wild Type < 2.5 BIC 2.5 to < 10 BIC 10 BIC < 4.0 DTG 4.0 to < 13 DTG 13 DTG < 2.5 EVG 2.5 EVG < 1.5 RAL 1.5 RAL White K, et al., European Workshop HIV & Hep Rome, Italy. Poster O-01. Tsiang M, et al., AAC 2016;60:
6 B/F/TAF Phase 3 Efficacy through Week 48 Study Population Comparator Efficacy Resistance Naïve DTG/ABC/3TC Non-inferior* Naïve DTG+FTC/TAF Non-inferior* Suppressed DTG/ABC/3TC Non-inferior Suppressed Boosted PI + 2 NRTIs Non-inferior Women, Suppressed E/C/F/(TAF or TDF) ATV+RTV + FTC/TDF Non-inferior 0** In five Phase 3 trials of 1,440 patients through Week 48 B/F/TAF had non-inferior efficacy with zero emergent resistance * For ART-naïve studies: Treatment outcomes [between treatment groups] were similar across subgroups by age, sex, race, baseline viral load, and baseline CD4+ cell count. 6 For virologically suppressed studies: Treatment outcomes between treatment groups were similar across subgroups by age, sex, race, and region. 5,6 One boosted PI regimen participant on DRV+RTV+ABC/3TC developed ABC mutation L74V ** One E/C/F/TAF participant developed FTC mutation M184M/I/V 1. Gallant J, et al. Lancet 2017;390: Sax P, et al. Lancet 2017;390: Molina JM, et al. CROI Boston, MA. Oral Daar E, et al. ID Week San Diego, CA. Oral LB-4 5. Kityo C, et al. CROI Boston, MA. Poster Gilead Sciences. Biktarvy US Prescribing Information. February 2018.
7 P r o p o r tio n w ith H IV -1 R N A < 5 0 c o p ie s /m L (% ) Rapid Suppression of HIV-1 RNA to < 50 copies/ml (Missing = Excluded Approach); 1489 & Week 4 76% 76% 80% Week 8 91% 92% 90% Week 12 96% 96% 95% Week 48 99% B/F/TAF 98% DTG/ABC/3TC 99% DTG+F/TAF B /F /T A F 3 0 D T G /A B C / D T G + F /T A F W e e k B/F/TAF vs. DTG/ABC/3TC or vs. DTG + F/TAF: rapid viral suppression and non-inferior efficacy at Week 48
8 White K, et al. CROI Boston, MA. Poster 532, Andreatta et al, CROI 2018 Boston, MA. Poster 506 Baseline Resistance Testing Screening Retrospective Baseline Testing Tx Naïve PR, RT Genotype GenoSure MG Monogram No IN Genotype PR, RT, IN Deep Sequencing SeqIT, Germany 15% frequency reported Switch Historical Genotype if available PR, RT, IN PR, RT, IN DNA Genotype GenoSure Archive* Monogram *Deep sequencing APOBEC hypermutation filter >15% frequency reported
9 White K, et al. CROI Boston, MA. Poster 532 Studies 1489 & 1490: B/F/TAF vs DTG-containing Regimens in Treatment-Naïve Adults Baseline Resistance-Associated Substitutions & FDA Snapshot Outcome Resistance Class Number of Participants, n (%) B/F/TAF n=634 Week 48 HIV-1 RNA <50 c/ml With Data 634 (100%) 576/634 (91%) Primary INSTI-R 6 (1.0%) 6/6 (100%) T97A 5 (0.8%) 5/5 (100%) Q148H (+G140S) 1 (0.2%) 1/1 (100%) Primary NRTI-R 16 (2.5%) 14/16 (88%) Any TAM 16 (2.2%) 14/16 (88%) Primary NNRTI-R 76 (12%) 68/76 (90%) K103N/S 41 (6.5%) 38/41 (93%) E138A/G/K/Q 24 (3.8%) 21/24 (88%) Primary PI-R 16 (2.5%) 15/16 (94%)
10 B/F/TAF Patient With Transmitted Resistance: Baseline White K, et al. CROI Boston, MA. Poster 532
11 P la s m a H IV -1 R N A (c o p ie s /m L ) B/F/TAF Patient with Transmitted Resistance: Baseline (2.5 10) B /F /T A F This is the first case of an ART-naïve patient with transmitted integrase resistance (G140S + Q148H) on B/F/TAF Virologic suppression was rapid and maintained from Week 4 to V is it D a te (W e e k s ) Baseline Genotype: NRTI: K70R NNRTI: K103N PI: none INSTI: G140S, Q148H
12 Andreatta K, et al. CROI Boston, MA. Poster 506 Studies 1844 & 1878: Suppressed Adults Switched from ABC/3TC/DTG or Boosted PI Baseline Resistance Data Resistance Class Number of Participants, n (%) B/F/TAF n=572 PR/RT Baseline Data 405 (71%) Historical Genotype 280 (49%) Baseline DNA Genotype 149 (26%) IN Baseline Data 170 (30%) Historical Genotype 23 (4%) Baseline DNA Genotype 149 (26%)
13 Andreatta K, et al. CROI Boston, MA. Poster 506 Studies 1844 & 1878: Suppressed Adults Switched from ABC/3TC/DTG or Boosted PI Baseline Resistance-Associated Substitutions & FDA Snapshot Outcome Resistance Class Number of Participants, n (%) B/F/TAF n=572 Week 48 HIV-1 RNA <50 c/ml Primary INSTI-R 1 (1.0%) 1/1 (100%) T97A 1 (1.0%) 1/1 (100%) Primary NRTI-R 52 (13%) 49/52 (94%) K65R 5 (1%) 5/5 (100%) M184V/I 30 (7%) 28/30* (93%) Any TAM 29 (7%) 28/29 (97%) Primary NNRTI-R 73 (18%) 71/73 (97%) K103N/S 46 (11%) 44/46 (96%) Primary PI-R 25 (6%) 25/25 (100%) M184V/I: 1 discontinued with HIV-1 RNA <50 c/ml at Week 4 and 1 had rebound at Week 8 and no detectable BIC in the plasma
14 Study 4030: B/F/TAF vs DTG + F/TAF or F/TAF in Suppressed Adults 4030 Study Design Phase 3, randomized, double-blind, multicenter, active-controlled study HIV-Suppressed Adults DTG + F/TDF or F/TAF Treatment HIV-1 RNA Naïve < 50 Patients c/ml Study egfr 102 and 103 CG 30 ml/min 1:1 N=260 N=260 B/F/TAF QD DTG + F/TAF Placebo QD DTG + F/TAF QD B/F/TAF Placebo QD ClinicalTrial.gov: NCT Key inclusion criteria Any NRTI, NNRTI or PI resistance are permitted HIV-1 <50 c/ml 6 months if documented or suspected NRTI resistance HIV-1 <50 c/ml 3 months if no NRTI resistance suspected or documented No documented resistance to INSTI or confirmed virologic failure (2 consecutive HIV-1 RNA 50 c/ml after achieving < 50 c/ml while on an INSTI-containing regimen) HBV and/or HCV coinfections allowed Primary Endpoint HIV-1 RNA 50 copies/ml at Week 48 by modified FDA-defined snapshot algorithm (4% non-inferiority margin) Week 48 Primary Endpoint
15 Conclusions ARV-naïve: Treatment with B/F/TAF, DTG/ABC/3TC, or DTG + F/TAF was highly efficacious through Week 48 Rapid viral load suppression by Week 4 Pre-existing drug resistance did not affect efficacy outcome One patient with transmitted INSTI resistance at G140S+Q148H treated with B/F/TAF achieved HIV-1 RNA was < 50 copies/ml at Week 4 and maintained suppression through Week 96 ARV Suppressed Switch: Switch to B/F/TAF from DTG +ABC/3TC or Boosted PI was highly efficacious through Week 48 Pre-existing drug resistance did not affect efficacy outcome High maintenance of suppression with M184V/I or 1-2 TAMs No patient developed resistance to study drugs on B/F/TAF or a DTG-based regimen Further studies of bictegravir and B/F/TAF in patients with virologic resistance are warranted
16 Acknowledgements Patients and their families Study Investigators and Site Staff Gilead Sciences B/F/TAF Team, Erin Quirk, Hal Martin, Devi Sengupta, Hiba Graham, Sean Collins, Huyen Cao, Tariro Makadzendge Clinical Virology: Rima Acosta, Kristen Andreatta, Madeleine Willkom, Danielle Porter, Nicolas Margot Seq-IT: Martin Daümer, Alex Thielen Monogram: Tim Persyn 16
ARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationResistance Characteristics of Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Madrid, November 2016 Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Disclaimer Presentation includes
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationTransmission of integrase resistance HIV
Transmission of integrase resistance HIV Charles Boucher, MD, PhD Clinical Virology, Dept. Viroscience, Erasmus Medical Center, Erasmus Universiy, The Netherlands Major resistance mutations (Stanford)
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationResistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
Viruses 2014, 6, 2858-2879; doi:10.3390/v6072858 Review OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical
More informationAcquired INSTI Resistance. Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Acquired INSTI Resistance Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting honoraria, speaker
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationGS-1489: STUDY DESIGN
A PHASE 3 RANDOMIZED CONTROLLED CLINICAL TRIAL OF BICTEGRAVIR IN A FIXED DOSE COMBINATION,, VS ABC/DTG/3TC IN TREATMENT-NAÏVE ADULTS AT WEEK 48 J. Gallant, A. Lazzarin, A. Mills, C. Orkin, D. Podzamczer,
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationAbstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo
WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationDisclosures. Goals/Format. Patient 1 12/8/18. Antiretroviral Therapy Management. Harry Lampiris: None. Gabriel Chamie: None.
Disclosures Antiretroviral Therapy Management Panel Discussion & Debate Medical Management of AIDS & Hepatitis December 6, 2018 Harry Lampiris, MD, 1 Gabriel Chamie, MD, MPH 2 Susa Coffey, MD, 2 and Vivek
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationDavid Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone
David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone 423-439-6245 Email cluckd@etsu.edu Recall newly approved antiretrovirals and their respective place in therapy
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationCL Vavro, 1 J Huang, 2 C Avatapally, 1 S Min, 1 and M Ait-Khaled 3. GlaxoSmithKline: 1 Research Triangle Park,NC, USA; 2 Toronto, ON, Canada; 3
Durable Efficacy and Limited Integrase Resistance Evolution in Subjects Receiving Dolutegravir After Failing Prior Integrase Inhibitor (INI) Regimens: Week 48 Results from VIKING-3 CL Vavro, 1 J Huang,
More informationIntegrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University
Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More information11/7/2016. Antiretroviral Therapy Strategies. Learning Objectives. After attending this presentation, participants will be able to:
Antiretroviral Therapy Strategies FORMATTED: 1/14/16 Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct Professor of Medicine The Johns Hopkins
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationARV Update: 2016 and Beyond Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital
ARV Update: 2016 and Beyond Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital Disclosures Scientific Advisory Panels: Gilead, Thera technologies, Merck,
More informationClinical considerations in switching antiretroviral therapy
Clinical considerations in switching antiretroviral therapy David Jilich Department of Infctious Diseases, 1st Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital 4th CEE Meeting
More informationCROI 2018 Update. Christian B. Ramers, MD, MPH, AAHIVS. Assistant Medical Director - Research/Special Populations Family Health Centers of San Diego
CROI 2018 Update Christian B. Ramers, MD, MPH, AAHIVS Assistant Medical Director - Research/Special Populations Family Health Centers of San Diego Assistant Clinical Professor UC San Diego School of Medicine
More informationAntiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016
More informationDidactic Series. CROI Update - II. Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15
Didactic Series CROI Update - II Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationFuture trends of drug resistance and prospects of antiviral therapy. Doug Richman International Drug Resistance Workshop Johannesburg 24 October 2018
Future trends of drug resistance and prospects of antiviral therapy Doug Richman International Drug Resistance Workshop Johannesburg 24 October 2018 The principles of HIV drug resistance are well established
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More information23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service,
23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service, SFVAMC March 23, 2016 Boston, MA, February 22-25, 2016 Disclosures
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationTerapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales
Terapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales clinicaloptions.com/hiv Eficacia en Ensayos Clínicos pivotales
More informationDolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.
Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance. D. Armenia 1, V. Borghi 2, F Forbici 3, C. Gori 3, A. Bertoli 1,
More informationWhat is the Virologic Support for Two-Drug Regimens?
What is the Virologic Support for Two-Drug Regimens? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationResistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationHIV Treatment Update
HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures Consulting, Advisory Boards,
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationOptimizing Clinical Utility of Integrase Inhibitors. Anton Pozniak MD FRCP
Optimizing Clinical Utility of Integrase Inhibitors Anton Pozniak MD FRCP INSTIs-Characteristics Rapid viral load decline Low rates resistance/ Transmitted Resistance Less chance of side effects Less pills,
More informationREASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
More informationDevelopment of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir
Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide () Bryan Baugh 1, Erika Van Landuyt 2, Simon Vanveggel 2, Herta
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationTerapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R
Terapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Gilead Board Member/Advisory Panel: MSD, Gilead, Janssen,
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More informationEvaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens
Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens Kimberly L. Garrison, Erik Mogalian, Heather Zhang, Grace Ma, Steve
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationTwo-drug combination passage among dolutegravir, rilpivirine, elvitegravir and Lamivudine
Two-drug combination passage among dolutegravir, rilpivirine, elvitegravir and Lamivudine T, Yoshinaga, S. Miki, T. Seki, T. Fujiwara Shionogi & Co., Ltd., Osaka, Japan Background A two-drug regimen may
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationCROI 2017 Update From Seattle
FORMATTED: 02/22/17 New York, New York: February 24, 2017 Update From Seattle Joseph J. Eron Jr, MD Professor of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina Update
More informationART=antiretroviral therapy; C=cobicistat; D=darunavir; F=emtricitabine; STR=single-tablet regimen; TAF=tenofovir alafenamide.
AMBER A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients Eron JJ, Orkin C, Gallant J, Molina J-M, Negredo E, Antinori A, Mills
More informationVIKING STUDIES. Efficacy and safety of dolutegravir. treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir treatment-experienced subjects (DTG) in UK/DLG/0083/14e(2) Date of preparation: February 2017 Prescribing information is available at the end of this
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationDidactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching
Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University
More informationCROI 2016: Top Ten for Clinicians
Hynes Convention Center. Boston, MA; US. Feb 22-25, 2016 CROI 2016: Top Ten for Clinicians Josep M Llibre Hospital Universitari Germans Trias i Pujol Fundació Lluita contra la SIDA Badalona, Barcelona
More informationHIV Treatment in 2018: What s New & How To Communicate Those Messages
HIV Treatment in 2018: What s New & How To Communicate Those Messages Jeffrey Kwong, DNP, MPH, ANP BC, FAANP Carole Treston, RN, MPH, FAAN Diego Villalba, Pharm D USCA September 7, 2018 The Association
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationImproving PI drug resistance scores. Jens Verheyen, MD Institute of Virology University Duisburg-Essen
Improving PI drug resistance scores Jens Verheyen, MD Institute of Virology University Duisburg-Essen Overview Why can all PI drug resistance scores be improved? Do we still need to improve PI drug resistance
More information